
InfuSystem Holdings, Inc
73
Recent developments include the reporting of Q3 2026 net revenues, a postponed earnings release, and coverage of quarterly earnings and operational performance.
- InfuSystem Holdings, Inc. reported third quarter 2026 net revenues of $37.6 million [N1].
- The company postponed its third quarter 2026 earnings release as of November 3, 2026 [N2].
- InfuSystem’s Q2 2026 earnings and revenues surpassed expectations, with an earnings call transcript available from August 2026 [N4][N5].
- The company reported Q4 2025 earnings that beat estimates [N6].
InfuSystem Holdings, Inc. operates with a business model generating revenues primarily from its medical equipment rental and related services, as indicated by its reported quarterly revenues and earnings. The company maintains liquidity with a current ratio above 2.5 and cash reserves exceeding $9 million as of Q3 2026. Recent quarterly earnings reports and earnings call transcripts provide transparency into operational performance and financial results. The company’s risk disclosures are available in its latest annual SEC filing.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. InfuSystem Holdings, Inc. reported third quarter 2026 net revenues of $37.6 million and net income of $3.156 million, with a basic EPS of $0.16 and diluted EPS of $0.15 as of September 30, 2026. The company held $9.108 million in cash and cash equivalents and maintained a current ratio of 2.68, indicating liquidity strength. The company postponed its Q3 2026 earnings release in early November 2026. Risk factors are disclosed in the 2025 Annual Report on Form 10-K filed February 27, 2026 [S1][S2][N1][N2].
The company has demonstrated consistent revenue generation and profitability in recent quarters, supported by liquidity ratios indicating financial stability. Positive earnings reports and surpassing revenue expectations in Q2 2026 reflect operational execution. The availability of earnings call transcripts and detailed SEC filings enhances transparency for stakeholders.
The postponement of the Q3 2026 earnings release may indicate operational or reporting challenges. The company operates in a competitive medical equipment rental market, which may face pricing pressures or regulatory risks. Limited disclosure on industry positioning and competitive moat constrains visibility into long-term resilience.
InfuSystem Holdings, Inc. appears to have a business model centered on medical equipment rentals and services, which may provide recurring revenue streams and customer relationships. The liquidity position and consistent quarterly revenues suggest operational stability. However, detailed competitive advantages or barriers to entry are not explicitly disclosed in the available data.
• Operational and Reporting Risks: The postponement of the Q3 2026 earnings release suggests potential challenges in financial reporting or operational execution that could affect stakeholder confidence.
• Market and Competitive Risks: Operating in the medical equipment rental sector exposes the company to competitive pressures, pricing risks, and regulatory compliance requirements that could impact revenues and margins.
• Liquidity and Financial Risks: While current liquidity ratios are strong, ongoing cash flow management is critical to sustain operations and fund growth initiatives.
Business trends: The company shows consistent revenue generation and profitability with liquidity strength as of Q3 2026.
Execution milestones: Recent quarterly earnings reports and earnings call transcripts provide transparency into financial performance.
Key risks: Operational and reporting challenges, competitive pressures in the medical equipment rental market, and liquidity management remain important considerations.
High visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- InfuSystem Holdings, Inc. reported net revenues of $37.6 million for the third quarter ended September 30, 2026 [N1].
- The company postponed its third quarter 2026 earnings release as of November 3, 2026 [N2].
- InfuSystem Holdings, Inc. had a net income of $3.156 million for Q3 2026, with basic earnings per share of $0.16 and diluted EPS of $0.15 as of September 30, 2026 [S2].
- As of September 30, 2026, the company held $9.108 million in cash and cash equivalents and had current assets of $47.913 million against current liabilities of $17.873 million, resulting in a current ratio of 2.68 and a cash ratio of 0.51 [S2].
- The company’s Q2 2026 earnings and revenues surpassed estimates, with an earnings call transcript available from August 2026 [N4][N5].
- InfuSystem Holdings, Inc. reported Q4 2025 earnings that beat estimates [N6].
- The company’s risk factors are detailed in its 2025 Annual Report on Form 10-K filed February 27, 2026 [S1].
- Liquidity ratios and financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice [S2].
Generated 2026-11-10
- N4
- S1 | 2026-02-27 | 10-K
- S2 | 2026-11-09 | 10-Q
- N1 | 2026-11-05 | www.nasdaq.com | InfuSystem Holdings, Inc. Reports Third Quarter 2026 Net Revenues of $37.6 million | https://www.nasdaq.com/articles/infusystem-holdings-inc-reports-third-quarter-2026-net-revenues-376-million
- N2 | 2026-11-03 | www.nasdaq.com | InfuSystem Holdings, Inc. Postpones Third Quarter 2026 Earnings Release | https://www.nasdaq.com/articles/infusystem-holdings-inc-postpones-third-quarter-2026-earnings-release
- N3 | 2026-10-06 | www.nasdaq.com | Biotech Stocks At 52-Week Highs - PCVX +31% On Phase 3 Results, INFU, ILMN +7%, CRL+7%, HTFL +5% | https://www.nasdaq.com/articles/biotech-stocks-52-week-highs-pcvx-31-phase-3-results-infu-ilmn-7-crl7-htfl-5
- N4 | 2026-08-11 | www.nasdaq.com | InfuSystem (INFU) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/infusystem-infu-q2-2026-earnings-call-transcript
- N5 | 2026-08-04 | www.nasdaq.com | InfuSystems Holdings, Inc. (INFU) Q2 Earnings and Revenues Surpass Estimates | https://www.nasdaq.com/articles/infusystems-holdings-inc-infu-q2-earnings-and-revenues-surpass-estimates
- N6 | 2026-02-24 | www.nasdaq.com | InfuSystems Holdings, Inc. (INFU) Q4 Earnings Beat Estimates | https://www.nasdaq.com/articles/infusystems-holdings-inc-infu-q4-earnings-beat-estimates
- N7 | 2026-02-19 | www.nasdaq.com | ICU Medical (ICUI) Q4 Earnings and Revenues Surpass Estimates | https://www.nasdaq.com/articles/icu-medical-icui-q4-earnings-and-revenues-surpass-estimates
- N8 | 2026-02-05 | www.nasdaq.com | Prestige Consumer Healthcare (PBH) Q3 Earnings Lag Estimates | https://www.nasdaq.com/articles/prestige-consumer-healthcare-pbh-q3-earnings-lag-estimates
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


